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ABSTRACT 
 
BACKGROUND:  In the first CONCORD study (2008), five-year survival for patients diagnosed with colon 
cancer during 1990-1994 in the U.S. was among the highest in the world (60%), but there were large 
racial disparities in most participating states.  The CONCORD-2 study (2015) enabled examination of 
survival trends during 1995-2009 for US states, by race and stage. 
 
METHODS:  We analyzed data from 37 state population-based cancer registries, covering approximately 
80% of the U.S. population, for patients diagnosed with colon cancer during 2001-2009 and followed 
through 2009.  Survival up to five years was corrected for background mortality (net survival) using 
state- and race-specific life tables, and age-standardized using the International Cancer Survival 
Standard weights.  Survival is presented by race (all, black, white), stage, state, and calendar period 
(2001–03 and 2004–09) to account for changes in methods used to collect stage. 
 
RESULTS: Five-year net survival increased 0.9% from 63.7% during 2001-2003 to 64.6% for 2004-2009. 
More black than white patients were diagnosed at distant stage in 2001-2003 (21.5% vs. 17.2%, 
respectively), and in 2004-2009 (23.3% vs 18.8%).  Survival improved for both blacks and whites, but 5-
year net survival was 10% lower for blacks than for whites during both 2001-2003 (54.7% vs. 64.5%) and 
2004-2009 (56.6% vs. 65.4%).  The absolute difference between blacks and whites decreased by only 1% 
during this decade. 
 
CONCLUSION:  Five-year net survival from colon cancer slightly increased over time. Survival among 
blacks diagnosed during 2004-2009 had still not reached the level of survival of whites diagnosed during 
1990-1994, some 15-20 years earlier. These findings suggest a need for more targeted efforts to 
improve screening and to ensure timely, appropriate treatment. 
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INTRODUCTION 
Worldwide, colorectal cancer is the third most common cancer diagnosed in men and the 
second most common cancer diagnosed in women.1  In developed countries, the incidence of colorectal 
cancer is higher and mortality is lower than in less developed countries.1  In the United States (U.S.), 
colon cancer comprises approximately two-thirds of incident colorectal cancer cases, and is the third 
most commonly diagnosed cancer among men and women.2  There were nearly 42,000 deaths from 
colon cancer alone in 2013, representing nearly 81% of colorectal cancer deaths.2 The incidence of colon 
cancer has been decreasing steadily since 2001; most recently, incidence declined an average of 3.1% 
per year between 2005 and 2014.2, 3  Mortality from colon and rectal cancers also has been declining for 
the past several decades, with the most rapid declines in the early 2000’s, which is likely due to 
screening.3, 4  Despite these overall reductions, colon cancer incidence and mortality rates remain 
substantially higher in blacks than other races/ethnicities, and higher among men than women.2  
Population-based cancer survival provides an indicator of the overall effectiveness of the health 
care system to deliver screening, early diagnosis, and evidenced-based treatment services to all people 
in the population being served.5  The first worldwide analysis of cancer survival (CONCORD) in 31 
countries for patients diagnosed during 1990-1994 and followed up to 1999 covered 42% of the US 
population.6 In the US, five-year survival for colon cancer was 60.1%, with lower survival among blacks 
(51%) compared with whites (61%).6 These differences may have resulted from black patients not having 
received the same standard of care, including access to screening, early diagnosis and optimal 
treatment, as white patients.6   Subsequent analysis of cancer survival worldwide (CONCORD-2) in 67 
countries compared patients diagnosed with one of 10 common cancers, including colon cancer, during 
1995-2009 and followed up to 2009 or later.  Five-year net survival for colon cancer was 60% or more in 
North America, 12 European countries and a few countries in Central and South America and Asia.7 For 
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the United States, five-year net survival for colon cancer increased from 61% for patients diagnosed 
during 1995-1999 to 65% in 2005-2009.7   
This study uses data from CONCORD-2 to provide the first detailed assessment of survival for 
colon cancer in the U.S. by state and stage at diagnosis and by race during 2001-2003 and 2004-2009. 
 
METHODS 
Data Source 
We used data from 37 population-based state cancer registries funded by either the Centers for 
Disease Control and Prevention (CDC)’s National Program of Cancer Registries or the National Cancer 
Institute’s Surveillance, Epidemiology and End Results (SEER) program, or both.8  These registries 
participated in the CONCORD-2 study,7 covered approximately 80% of the United States population, and 
consented to the inclusion of their data in the more detailed analyses reported here.  This analysis 
included 813,103 males and females (aged 15-99 years) diagnosed with invasive colon cancer between 
2001-2009 with follow-up through December 31, 2009. As defined in the original study, for colon cancer, 
we included both the colon and rectosigmoid junction (ICD-O-3 codes:  C18.0–C18.9, C19.9).7   Primary, 
invasive cancers were included regardless of whether the patient has had a previous cancer. If the 
patient was diagnosed with two or more cancers of the colon during 2001-2009, only the first cancer 
was considered in the survival analyses. 
Patients were grouped by year of diagnosis into two calendar periods (2001-2003 and 2004-
2009) to reflect changes in the methods used by US cancer registries to collect data on stage at 
diagnosis. From 2001 to 2003, the majority of U.S. cancer registries directly assigned Surveillance, 
Epidemiology and End Results (SEER) summary stage (SS2000) to their cases;9 while in 2004, registries 
began using the Collaborative Staging System (CS) to derive SS2000.10  Information on stage was not 
available for two states (Maryland and Wisconsin), or for Rhode Island for patients diagnosed during 
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2004-2009. Therefore, these states are not included in national estimates of survival by stage during 
these calendar periods. 
 
Statistical analysis 
Net survival (1-, 3-, and 5-year), with 95% confidence intervals (CI), was estimated for patients 
diagnosed during 2001-2003 and 2004-2009, by state, race and stage at diagnosis using the Pohar Perme 
estimator.  The Pohar Perme estimator allows for an unbiased estimation of net survival, i.e. the 
probability for patients to survive their cancer up to a given time since diagnosis, after controlling for 
other causes of death (background mortality).11  To control for wide differences in background mortality 
among participating states, life tables of all-cause mortality in the general population of each state were 
constructed from the number of deaths and the population by single year of age, sex, calendar year and, 
where possible, by race (Black, White) using a flexible Poisson model.12  Methods for constructing life 
tables have been published.13  
For patients diagnosed during 2001-03, the cohort approach was used to estimate net survival, 
since all patients had been followed up for at least five years by December 31, 2009.  The complete 
approach was used to estimate five-year net survival for patients diagnosed during 2004-09, because 
five years of follow-up data were not available for all patients.  Net survival was estimated for five age 
groups (15-44, 45-54, 55-64, 65-74, and 75-99 years). All estimates were age-standardized using the 
International Cancer Survival Standard (ICSS) weights.14  If two or more of the five age-specific estimates 
could not be obtained, only pooled, unstandardized survival estimates for all ages combined were 
presented.  All unstandardized estimates are italicized in Supporting Tables 2 and 3.  The overall results 
for colon cancer were presented; however, state-specific results were reported in Supporting Tables 1, 2 
and 3. Trends, geographic variations and differences in age-standardized survival by race are presented 
graphically in bar charts and funnel plots.15   Funnel plots of net survival for the two calendar periods 
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provide a simple and informative display of geographic variations or trends in population-based cancer 
survival measures (e.g. age-standardized net survival) in the United States, by race and state.  
Specifically, the plots show how much a particular survival estimate deviates from the pooled estimate 
of US registries (the target represented in the plot by the horizontal line) given the precision of each 
estimate. 15 More detail on the data and methods is provided in an accompanying article by Allemani et 
al.16 
 
RESULTS 
Table 1 shows the distribution of patients by race, stage and calendar period of diagnosis.  Of 
the 278,382 patients diagnosed in 2001-2003, 85.7% (n=238,690) were white and 10.7% (n=29,658) 
were black. Of the 534,721 patients diagnosed in 2004-2009, a slightly smaller percentage were white 
(83.7%; n=447,569) and slightly more were black (11.9%; n=63,704). For all races combined, there was 
an increase in the proportion of patients diagnosed at localized and distant stages between 2001-2003 
and 2004-2009 (from 34.2% to 37.8% and from 16.6% to 19.3%, respectively) and a decrease in the 
proportion diagnosed at regional stage (39.3% to 34.9%; Table 1). The percentage of patients with 
unknown stage decreased from 8.9% to 7.9%. Among blacks, the proportion of patients diagnosed at a 
localized stage increased from 29.1% to 33.8%; at a regional stage decreased from 37.4% to 32.7%; and 
at distant stage slightly increased from 21.5% to 23.3%.  Among whites, the proportion of patients 
diagnosed with localized stage increased from 34.8% to 38.4%; with regional stage decreased from 
39.5% to 35.2%; and with distant stage increased from 17.2% to 18.8%. Between the two calendar 
periods, the absolute difference in the proportion of black and white patients diagnosed at localized 
stage fell slightly (from 5.7% to 4.6% higher among white than black patients); and was essentially 
unchanged for regional (from 2.1% to 2.5% higher among white than black patients) and distant stages 
(4.3% to 4.5% lower among white than black patients). In nearly all states, the proportion of black 
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patients diagnosed with localized stage was lower than for white patients in both calendar periods 
(Supporting Table 1). 
Between the two calendar periods, there were small increases in 1-, 3-, and 5-year net survival 
from 81.8%, 69.5% and 63.7%, respectively, in 2001-2003, to 82.9%, 70.7%, and 64.6%, respectively, in 
2004-2009 (Table 2). Blacks had slightly lower 1-, 3- and 5-year survival than whites during both calendar 
periods but survival among blacks increased more than among whites. The absolute difference in 
survival between blacks and whites declined slightly between 2001-2003 and 2004-2009 (from 6.0% to 
5.3% at 1-year, 8.8% to 8.3% at 3-years, and 9.8 % to 8.8% at 5-years).  Survival up to five years after 
diagnosis was lower in blacks than in whites in nearly all states, both in 2001-2003 and 2004-2009 
(Supporting Table 2).  
Five-year net survival for colon cancer was highest for patients diagnosed at a localized stage, 
followed by regional and then distant stages (Table 3).  There was no change in 5-year net survival 
between 2001-2003 and 2004-2009 for patients diagnosed at localized stage, but survival increased for 
those diagnosed at regional (68.7% to 70.2%) and distant stages (11.1% to 13.8%).    
Blacks experienced poorer 5-year net survival than whites, at all stages and in both periods of 
diagnosis; however, the absolute difference in survival between blacks and whites decreased slightly 
between the two calendar periods for localized stage (from 6.7% to 4.9%) and remained essentially 
unchanged for regional and distant stages. Survival up to five years after diagnosis was lower in blacks 
than in whites in nearly all states, both in 2001-2003 and 2004-2009 (Supporting Table 3). 
As shown in Figure 1, overall five-year net survival increased by 1.0%.  Survival ranged from 
59.8% to 69.5% in 2001-2003 and from 60.9% to 69.7% in 2004-2009 across the 37 participating states 
(Supporting Table 3). The largest increase in survival was 5.0%, while the largest decrease in survival was 
-6.6%.   
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Funnel plots of net survival for 2001-2003 and 2004-2009 show striking geographical and racial 
variation in survival (Figure 2).  Although 5-year survival from colon cancer slightly increased between 
2001-2003 and 2004-2009 in most states, it was lower for blacks (50-60%) than for whites (60-70%) in 
nearly every state for which data were available.   In 2004-2009, there was a slight shift upwards in 
survival and some overlap whereby the highest survival for blacks was similar to the lowest survival for 
whites. In all 26 states for which a survival estimate could be obtained for blacks, survival was 
systematically lower than the pooled estimate of US registries.  
 
DISCUSSION  
This population-based study is the largest to date showing trends in survival up to 5 years after 
diagnosis for colon cancer by stage, race and state. There was a modest increase in 5-year colon cancer 
survival between 2001-2003 and 2004-2009 for patients diagnosed at regional or distant stages but not 
for patients with locally staged cancer where survival was already high (90%). Survival was not equal 
between states or by race. Five-year survival varied considerably among states but improved in most 
states between the two calendar periods. Five-year net survival was much lower in black patients than 
white patients at all stages of disease and this racial disparity only decreased by 1% over the decade.  
Changes in survival likely reflect changes in screening, stage of diagnosis and treatment.17 The 
small increases in 1-, 3- and 5-year colon cancer survival between the two calendar periods may reflect 
gains in survival achieved in the first calendar period.  Since 1998, Medicare has covered annual fecal 
occult blood test and sigmoidoscopy every 4 years for average risk beneficiaries aged 50 years and older.  
In July 2001, coverage was expanded to include colonoscopy for average-risk individuals every 10 years.  
As a result, there was a rapid increase in the use of colonoscopy and an increased probability of 
diagnosis at an early stage among older adults.18  Since 2000, screening has increased for persons aged 
50-75 years and colonoscopy has become the most commonly used test, but screening test use among 
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blacks has remained lower than among whites.19 In this study, there was an increase in earlier stage at 
diagnosis for both black and white patients.  However, a larger proportion of blacks than whites were 
diagnosed at later stages of disease, which may be partially explained by historically lower screening 
rates among blacks compared with whites.20, 21 Finally, the uneven distribution of access to high-quality 
treatment may explain the minimal improvement in survival.  Populations that reside in low 
socioeconomic and/or rural areas are less likely to receive high-quality treatment for colon cancer than 
their counterparts.22   
The wide variation in survival observed between states may reflect differences in access to 
screening and high-quality treatment. States that have a greater proportion of rural and lower 
socioeconomic status (SES) populations tend to fare worse in colon cancer outcomes.23Populations with 
low SES, including the uninsured, are less likely to be up-to-date for colorectal (CRC) screening according 
to recommendations.  In 2015, the lowest colorectal cancer screening use was reported by persons who 
were uninsured (25.1%).19  Access to and receipt of high quality treatment varies geographically. 
Residents of rural and/or low SES neighborhoods have more limited access to hospitals that offer high 
quality treatment than residents of urban areas or high-SES neighborhoods.  One study found that 
patients treated in hospitals without Commission on Cancer designation or with lower surgical volumes 
had lower odds of adequate lymph node assessment, 24 a key factor in staging and treatment.  Another 
study found that colon cancer patients residing in low- and lower-middle-SES neighborhoods had 
decreased odds of receiving surgery and chemotherapy than patients residing in high SES 
neighborhoods.22  It also found that rural residents had an increased risk of death from colon cancer that 
was explained by treatment differences and neighborhood SES.22 
Five-year survival showed modest improvement between the two calendar periods for patients 
diagnosed with regional and distant stage colon cancers.  Advances in treatment have improved survival 
for later stage disease.25-27 In the late 1980s, 5-fluorouracil-based adjuvant chemotherapy for patients 
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with surgically re-sectable Stage III colon cancer was introduced.28, 29  In clinical trials, this treatment 
reduced mortality from colon cancer by as much as 30%.  Later, the 1990 National Institutes of Health 
expert panel recommended that patients with Stage III colon cancer receive adjuvant therapy with 5-
fluorouracil-based chemotherapy and levamisole.26  Since that time, there have been new additions to 
adjuvant treatment that have a survival advantage over these therapies. After 2004, oxaliplatin in 
combination with fluoropyrimidine-based therapy became the predominant adjuvant treatment for 
both stage II and stage III colon cancer.27 Improvements in outcome in metastatic colorectal cancer were 
associated with an increased use of hepatic resection in some patients during 1998 to 2006 and 
advancements in medical therapy from 2004 to 2006.30  
Five-year net survival for colon cancer among black patients diagnosed in 2004-2009 has yet to 
reach that of white patients diagnosed 15-20 years earlier.  In the first CONCORD study, cancer survival 
among blacks diagnosed during 1990-94 was 51.5% in men and 51.0% in women, while survival in 
whites was 60.5% and 60.8%, respectively.6 Survival among black patients diagnosed during 2004-2009 
was 54.5% in men and 58.6% in women compared with 64.5% and 66.4%, respectively among whites.16  
The disparities observed may reflect differences in access to screening and receipt of high quality health 
care.17, 31, 32 Factors that have been shown to be associated with racial disparities in survival include 
differences in socioeconomic status,33 tumor biology, sub-site (proximal versus distal)34, stage at 
diagnosis,3 comorbid conditions limiting treatment choices,4, 25, 33 and access to timely, high-quality 
treatment.35, 36 
Blacks had lower stage-specific 5-year survival than whites.  The decrease in the magnitude of 
the disparities was present, though small, between the two calendar periods at every stage.  Several 
studies have found that black colorectal cancer patients are less likely than white patients to receive 
appropriate surgery, adjuvant chemotherapy, and radiation treatments.33, 35  In settings where black and 
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white patients with similarly staged disease receive comparable cancer treatment, survival differences 
by race are reduced.37   
 
Clinical Perspective 
  To further reduce colon cancer incidence and mortality and improve survival, increased efforts 
are needed to ensure that people are offered screening at the appropriate age, receive timely diagnostic 
follow-up, get high-quality treatment and have adequate post-treatment surveillance. For colon cancers 
diagnosed at invasive stages, the wide differences in net survival between blacks and whites, and by 
state, reflect both the uneven use of effective treatment and the distribution of factors that affect 
recommendation of and uptake of treatment (e.g. SES, health literacy, health care access, insurance 
coverage, physician recommendation, and patient factors such as health beliefs, culture, and co-
morbidities). Additional investigation may be needed to assess adherence to standards of treatment for 
colon cancer and to develop effective interventions to improve recommendation of and adherence to 
high-quality treatment.   
Recent research has shown that primary tumor location may play a role in survival for colon 
cancer.  Patients whose primary tumors originate on the left side of the colon survive significantly longer 
than those whose tumors originate on the right side.38 Right-sided colon cancers are more likely to have 
poorly differentiated tumors and to be diagnosed at a more advanced stage, both factors that are 
associated with poor survival. 39 Additional research is needed to understand better the tumor biology 
behind these differences in survival to inform whether there is a need to change the approach to colon 
cancer treatment by managing colon cancer by tumor location.  Ultimately, better understanding of the 
differences in tumor biology may also affect the choice of treatment modalities, specifically the 
chemotherapy regimens that are used for right- versus left-sided colon cancer. 
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Cancer Control Perspective 
CDC’s efforts to reduce the burden of colon cancer in the United States have largely focused on 
colorectal cancer screening, awareness and education.  CDC’s Colorectal Cancer Control Program 
(CRCCP) funds states, universities and tribal organizations to partner with health care systems to 
implement evidence-based interventions to increase the use of CRC screening tests for adults aged 50-
75 years.8, 40 In some states, the program also provides screening and follow up for positive tests for 
adults aged 50–64 years who are uninsured or underinsured and below 250% of the federal poverty 
level.40  In addition to the CRCCP, the National Comprehensive Cancer Control Program brings together 
key partners and organizations to develop and implement plans to address the cancer burden.8, 41  
Finally, CDC and its partners are leading a national initiative to increase CRC screening rates to 80% by 
2018.42  By achieving this goal, it is estimated that approximately 280,000 new cancer cases and 200,000 
cancer deaths will be averted within 20 years.42 
To help achieve this goal, public health professionals could partner with healthcare systems to 
help design processes that ensure patients receive quality care along the entire continuum of care from 
screening to diagnosis to treatment and survivorship, including the provision of culturally and 
linguistically appropriate services or implementation of the National CLAS Standards.43 Cancer screening 
registries can be used to improve follow-up among patients with positive screening tests and to 
implement evidence-based interventions, such as reminder systems.44 Further, to address the disparities 
observed in this study, more research is needed to explore the geographic distribution of screening and 
treatment services, and factors contributing to the use or non-use of these services, within and between 
states, and what can be done to improve access in low-access areas and in medically underserved 
populations. 
 
Strengths and Limitations 
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 The CONCORD-2 study is the largest comparative study of population-based survival in the U.S. 
and includes high quality data that covers 80% of the U.S. population. The overall quality of the 
CONCORD-2 data, the rigorous statistical methods used and the large population coverage are such that 
the results presented provide a broad and comprehensive overview of trends and racial disparities in 
survival among cancer patients diagnosed in the U.S.   Details on the strengths and limitations of these 
data are described elsewhere.45   For colon cancer, there was a high percentage of microscopically 
confirmed colon cancer cases (97.6%), with no differences by race, indicating a high degree of clinical 
investigation of patients in the U.S.16 Further, considering the population-based nature of this study, the 
proportion of colon cancer cases with unknown stage was remarkably low (8.9% for 2001-03 and 7.9% 
for 2004-09).  The stage was unknown slightly more often in blacks than in whites (11.9% vs. 8.6% in 
2001-03 and 10.2% vs. 7.5% in 2004-09). However, the completeness of stage information is remarkably 
high, and the differences in the proportion of unknown stage by race are not large. We would not 
expect these differences to affect the comparison of stage-specific survival by race. 
Our findings are subject to some limitations.45  First, caution should be used in comparing these 
results with other published studies using U.S. data.  In the CONCORD-2 study, cancers that occur in the 
sigmoid-rectum junction were classified as colon cancer.  In the U.S., this site is typically classified as 
cancer of the rectum. Second, there were several state estimates that fell outside the control limits as 
shown in the funnel plots.  For estimates that were above the control limits (i.e., survival was higher 
than expected), caution should be used in interpreting these results because these registries may have 
not captured all particularly for patients who leave the United States between the time of their 
diagnosis and death.   
 
Conclusions 
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The United States has made some progress in improving survival for patients diagnosed with 
colon cancer, particularly for patients whose cancers were diagnosed at a regional or distant stage. 
However, progress was not uniform across all states and by race. Five-year survival among blacks 
diagnosed during 2004-2009 had still not reached the level of survival of whites diagnosed during 1990-
94, some 15-20 years earlier. More work needs to be done to reduce the wide disparities observed by 
state and race and targeted interventions are needed to reach the most vulnerable populations. Trends 
in population-based cancer survival can be used to inform policy and can serve as a benchmark for 
states to measure the impact of their cancer control programs. 
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Figures and Tables  
Figure 1- Colon cancer: 5-year age-standardized net survival (%) for patients (15-99 years) diagnosed during 2001-2003 and 2004-2009, and 
absolute change (%): states grouped by US Census Region. 
 
Note: States are ranked within Census Region by the survival estimate for 2004-2009.  
Note: Dark colors – states affiliated with the National Program of Cancer Registries (NPCR); pale colors – states affiliated with the Surveillance, 
Epidemiology and End Results (SEER) Program. * Registries affiliated with both federal surveillance programs. Change (%) not plotted because at 
least one calendar period estimate was not age-standardized.  
 
Figure 2. Colon cancer: 5-year age-standardized net survival (%) for patients (15-99 years), by state, race and calendar period of diagnosis.  
 
Note: the pooled (US) survival estimates for each calendar period are shown by the horizontal (solid) line with corresponding 95.0% and 99.8% 
control limits (dotted lines). 
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Table 1. Colon cancer: number of cases for males and females (15-99 years) diagnosed 2001-2009 and distribution (%) by SEER Summary Stage 
2000, race and calendar period of diagnosis. 
  2001-2003  
 
2004-2009 
Stage  All races  White  Black   All races  White  Black 
              
No. of patients 278,382  238,690  29,658   534,721  447,569  63,704 
Localized (%) 34.2  34.8  29.1   37.8  38.4  33.8 
Regional  (%) 39.3  39.5  37.4   34.9  35.2  32.7 
Distant (%) 17.6  17.2  21.5   19.3  18.8  23.3 
Unknown (%) 8.9  8.6  11.9   7.9  7.5  10.2 
 
 
Table 2.  Colon cancer: age-standardized net survival (%) at 1-, 3- and 5-years for males and females (15-99 years) diagnosed 2001-2009, by race 
and calendar period of diagnosis. 
 2001-2003  2004-2009 
 All races White Black  All races White Black 
Years 
NS 
(%) 95% CI 
NS 
(%) 95% CI 
NS 
(%) 95% CI 
 
NS (%) 95% CI 
NS 
(%) 95% CI 
NS 
(%) 95% CI 
                          
                                                   
1 81.8 81.6 - 81.9 82.3 82.1 - 82.5 76.3 75.8 - 76.8  82.9 82.8 - 83.0 83.4 83.2 - 83.5 78.1 77.8 - 78.5 
3 69.5 69.3 - 69.7 70.3 70.1 - 70.6 61.5 60.8 - 62.1  70.7 70.5 - 70.8 71.4 71.3 - 71.6 63.1 62.6 - 63.6 
5 63.7 63.4 - 63.9 64.5 64.3 - 64.8 54.7 54.0 - 55.5  64.6 64.4 - 64.9 65.4 65.2 - 65.7 56.6 55.9 - 57.3 
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Table 3.  Colon cancer: 5-year age-standardized net survival (%) for males and females (15-99 years) diagnosed 2001-2009, by SEER Summary 
Stage 2000, race and calendar period of diagnosis. 
 2001-2003  2004-2009 
 
All races White Black  All races White Black 
SEER 
Summary 
Stage 
NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI  NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI 
                                                   
All stages 63.7 63.4 - 63.9 64.5 64.3 - 64.8 54.7 54.0 - 55.5  64.6 64.4 - 64.9 65.4 65.2 - 65.7 56.6 55.9 - 57.3 
Localized 89.8 89.4 - 90.1 90.2 89.8 - 90.5 83.5 82.3 - 84.8  89.7 89.4 - 90.0 90.0 89.6 - 90.3 85.1 83.9 - 86.2 
Regional  68.7 68.3 - 69.0 69.3 68.9 - 69.6 62.3 61.1 - 63.4  70.2 69.8 - 70.6 70.7 70.2 - 71.1 63.9 62.6 - 65.1 
Distant 11.1 10.8 - 11.4 11.4 11.1 - 11.8 7.9 7.2 - 8.6  13.8 13.4 - 14.1 14.2 13.8 - 14.6 10.9 10.0 - 11.7 
Unknown 51.9 51.1 - 52.6 52.1 51.2 - 53.0 46.9 44.9 - 48.9  49.4 48.6 - 50.2 49.4 48.5 - 50.2 45.4 43.5 - 47.3 
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Supporting Table 1. Colon cancer: number of cases for males and females (15-99 years) diagnosed 2001-2009 and distribution (%) by SEER 
Summary Stage 2000, race, calendar period of diagnosis, and US Census Region and States. 
 
Note: Information on stage was not available for two states (Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 
2009.   
 
Supporting Table 2.  Colon cancer: age-standardized net survival (%) at 1-, 3- and 5-years for males and females (15-99 years) diagnosed 2001-
2009, by race, calendar period of diagnosis, and US Census Region and States.  
 
Note: Unstandardized estimates are italicized. 
 
Supporting Table 3.  Colon cancer: 5-year age-standardized net survival (%) for males and females (15-99 years) diagnosed 2001-2009, by SEER 
Summary Stage 2000, race, calendar period of diagnosis and US Census Region and States. 
 
Note: Information on stage was not available for two states (Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 
2009.    Unstandardized estimates are italicized.  
 
 
 
